CTAD
@CTADconference
Followers
3K
Following
2K
Media
1K
Statuses
6K
The Clinical Trials on Alzheimer's Disease conference (CTAD) is a meeting focused entirely on Alzheimer’s Disease Therapeutic Trials
San Diego, CA, USA
Joined April 2017
At #CTAD25, the Non-Pharmacological & Lifestyle Interventions session spotlighted rising researchers: 🔹B. Ku – gardening-based therapy improving mood & executive function 🔹I. Antonsdottir – group CBTi for sleep in early AD dyads
0
0
2
@startuphealth #AlzMoonshot portco, @veravas did a great job at the #CTAD2025 Biotech Showcase! Did you catch their poster? P199 If you are interested in #tau pathology, It’s worth a look! @CTADconference
0
2
0
At #CTAD25, the Digital Health & Early Detection session spotlighted rising researchers: 🔹K. Harrington – remote AI verbal learning app (LILA) 🔹G. Pilonieta – MRI use for ARIA in lecanemab patients 🔹M. Ritchie – enrollment patterns in preclinical AD trials
0
1
1
At #CTAD25, the Biomarkers & Mechanisms of Frailty & Cognitive Decline session spotlighted rising researchers: 🔹D. Angioni – p-tau181 linked to cognitive & physical decline 🔹I. Skylar-Scott– proteomic signatures of cognitive reserve 🔹L. Herriott– Brainshuttle antibody modeling
0
2
2
At #CTAD25, the Translational Therapeutics & Clinical Innovation session spotlighted rising researchers: 🔹M. Leuchter – precuneus rTMS in Alzheimer’s 🔹E. Clark – escitalopram for neuropsychiatric symptoms 🔹M. Wong – CBF biomarkers predicting response in vascular MCI
0
2
2
New data release! We’re excited to share new research on continued treatment, real-world experience, and more at the Clinical Trials on Alzheimer’s Disease (CTAD) conference (@CTADconference . We thank everyone involved for their hard work. https://t.co/OI6cN1kdp6
2
2
6
Nice job by Jeff Cummings in presenting and facilitating the semaglutide data presentations at #CTAD2025 Nice recognition from the floor on trial execution, still lots of questions and more data coming at #ADPD2026 @CTADconference Slides on @novonordisk website
0
2
1
Today at #CTAD2025 we presented clinical trial data on our treatment for early #AlzheimersDisease. Read more: https://t.co/S8bZqnSl22
#AlzheimersDisease #ClinicalResearch #CTAD2025
0
2
5
We’re pleased to share an update on our investigational anti-MTBR tau antibody. Read more: https://t.co/NRMEmclEXR
#AlzheimersDisease #ClinicalResearch #CTAD2025
1
2
7
We’re looking forward to sharing our latest research on Alzheimer’s disease at #CTAD25 in San Diego and hope to see you there. Learn more about the data we’re presenting: https://t.co/wUjb8fjxwx
@CTADconference-Congress #AlzheimersDisease
0
3
5
Join #CTAD25 remotely and stay up to date on the latest advances in #Alzheimer’s #clinicaltrials. Watch all sessions live or on-demand for 10 months, explore the virtual poster hall, and connect with #speakers and attendees. Register remotely: https://t.co/TeI0hNbzoe
0
1
2
Can GLP‑1s slow cognitive decline? Results from the EVOKE & EVOKE+ trials are expected soon. As Dr. Fillit shares, the results could show how targeting the underlying biology, like inflammation, metabolism, & vascular, may transform #Alzheimer's treatment. https://t.co/fTnl0p7boO
reuters.com
Studies from Novo Nordisk due early next month will give the strongest indication yet of whether blockbuster GLP-1 drugs - a class being used by millions for diabetes and weight loss - can slow...
0
1
3
⏳ Only two weeks left! #CTAD25 is almost here. Join us Dec 1–4 in San Diego or online for breakthrough #Alzheimer’s science — practice-changing trial updates, new mechanisms, top #oralsessions & a rich poster hall. Register: https://t.co/TeI0hNbzoe
0
1
0
🧠 400+ posters at #CTAD25! Dive into the latest in #Alzheimers & #Dementia research from biomarkers & digital outcomes to new therapies and AI in clinical trials. ☕️ Join the Poster Walking Tour every morning and meet the scientists behind the studies. https://t.co/TeI0hNb1yG
0
2
3
Great collaboration between our partner @TheADDF and our official journal @jpreventionalz1 on this special issue dedicated to the future of combination therapies in Alzheimer’s disease.
The ADDF is proud to partner with @jpreventionalz1 on a landmark issue on combination therapies. Just as they transformed cancer care, combination therapies are poised to do the same for Alzheimer’s, providing a roadmap for advancing critical research. https://t.co/Jkzn3QUc03
0
3
4
🚨 Only One Month Away! #CTAD25 brings the latest Alzheimer’s & dementia trial breakthroughs to San Diego, Dec 1–4. Hear new data first, connect with top researchers & shape the future of brain health. 🔗Register today: https://t.co/TeI0hNbzoe
0
1
2
🧠#CTAD25 is coming! Dec 1–4 | San Diego & Online Discover late-breaking data, cutting-edge methods, and new #Alzheimer’s trial results in #symposia, oral sessions & posters. Join the global Alzheimer’s community 🔗 https://t.co/TeI0hNbzoe
0
2
0
Discover the Late-Breaking Highlights at #CTAD25! 🧪Phase 3 results: Semaglutide in early AD (EVOKE & EVOKE+) 🧬New data from the Neurodegeneration Proteomics Consortium (ApoE, aging clocks) 💉Update on lecanemab SC formulation for early AD 🔗 https://t.co/TeI0hNb1yG
0
1
1
📢 The #CTAD25 Final Program is online! Join us in San Diego or virtually, Dec 1–4, 2025. Explore world-class sessions, late-breaking science & major clinical trial readouts shaping the future of #Alzheimers and #Dementiaresearch. 🔗The Final Program: https://t.co/xrEms1OclJ
0
3
3
⏰Last day! Early-bird for #CTAD25 ends today (Oct 15). Register now to secure your access to the leading #Alzheimer’s & dementia research meeting—in-person (Last chance to register for in-person attendance) or online. 🔗 https://t.co/TeI0hNbzoe
0
2
0